Search results for "Alzheimer"
showing 10 items of 706 documents
Potential Involvement of Impaired Venous Outflow from the Brain in Neurodegeneration: Lessons Learned from the Research on Chronic Cerebrospinal Veno…
2019
About 10 years ago, the so-called chronic cerebrospinal venous insufficiency syndrome was discovered. This clinical entity, which is associated with extracranial venous abnormalities that impair venous outflow from the brain, was initially found exclusively in multiple sclerosis patients. Currently, we know that such venous lesions can also be revealed in other neurological pathologies, including Alzheimer’s and Parkinson’s diseases. Although direct causative role of chronic cerebrospinal venous insufficiency in these neurological diseases still remains elusive, in this paper, we suggest that perhaps an abnormal venous drainage of the brain affects functioning of the glymphatic system, whi…
Regulated Proteolysis of RAGE and AβPP as Possible Link Between Type 2 Diabetes Mellitus and Alzheimer's Disease
2009
Epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of developing Alzheimer's disease (AD). In T2DM, the elevated blood glucose level promotes formation of advanced glycation end products (AGEs). The receptor for AGEs (RAGE) is a type I membrane-protein and is also able to import amyloid-beta (Abeta) from the blood across the blood-brain-barrier into the brain. Oligomeric Abeta peptides disturb synaptic function in the brain and are believed to contribute to the development of AD. Abeta peptides are released from the amyloid-beta protein precursor (AbetaPP) after sequential proteolysis by beta- and gamma-secretases but alpha-secretase-mediated cleavage…
CHF2819: Pharmacological profile of a novel acetylcholinesterase inhibitor
2002
CHF2819 is a novel orally active acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer's disease (AD). CHF2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE). Moreover, CHF2819 is more selective for inhibition of central (brain) AChE than peripheral (heart) AChE. In vivo CHF2819, 0.5, 1.5, and 4.5 mg/kg p.o., significantly and in dose-dependent manner increased acetylcholine (ACh) levels in hippocampus of young adult rats. Moreover, aging animals, with lower basal ACh levels than young adult rats, also exhibit a marked increase in hippocampal levels of this neurotransmitter after administ…
The search for novel avenues for the therapy and prevention of Alzheimer's disease.
2006
The prevention and therapy of neurodegenerative disorders in the elderly is one of the greatest challenges facing molecular medicine today. Alzheimer's is an excellent example of a disease being studied by many groups worldwide. Indeed, while many molecular details of this disorder have been elucidated in the last two decades, there are still no strictly causal therapies available. While certain symptomatic pharmacological treatments are frequently employed, current molecular medicine research is focused on central Alzheimer-associated biochemical changes to find the key switch that turns the detrimental Alzheimer process on. Although amyloid beta proteins and tau proteins are the focus of …
Immune-Inflammatory Responses and Oxidative Stress in Alzheimers Disease: Therapeutic Implications
2010
Alzheimer's disease (AD) is a heterogeneous and progressive neurodegenerative disease which in Western society mainly accounts for clinical dementia. AD has been linked to inflammation and oxidative stress. Neuro-pathological hallmarks are senile plaques, resulting from the accumulation of several proteins and an inflammatory reaction around deposits of amyloid, a fibrillar protein, Abeta, product of cleavage of a much larger protein, the beta-amyloid precursor protein (APP) and neurofibrillary tangles. Inflammation clearly occurs in pathologically vulnerable regions of AD and several inflammatory factors influencing AD development, i.e. environmental factors (pro-inflammatory phenotype) an…
SenseCam: A new tool for memory rehabilitation?
2016
International audience; The emergence of life-logging technologies has led neuropsychologist to focus on understanding how this new technology could help patients with memory disorders. Despite the growing number of studies using life-logging technologies, a theoretical framework supporting its effectiveness is lacking. This review focuses on the use of life-logging in the context of memory rehabilitation, particularly the use of SenseCam, a wearable camera allowing passive image capture. In our opinion, reviewing SenseCam images can be effective for memory rehabilitation only if it provides more than an assessment of prior occurrence in ways that reinstates previous thoughts, feelings and …
Preclinical phase of Alzheimer's disease: Guideline for recognition and study of patients with mild cognitive impairment
2002
Musiikki muistojen herättäjänä
2013
Tässä kandidaatintutkielmassa on tutkittu musiikin vaikutusta Alzheimer-potilaan muistamiseen ja elämänkokemusten muistelemiseen. Tutkielman tarkoituksena on selvittää, millaiseksi Alzheimer-potilas kokee muistamisen elämänvaiheidensa musiikin avulla ja onko musiikilla vaikutusta muistisairaan muistamisprosessiin. Tutkimus on laadullinen tapaustutkimus, jonka aineisto koostuu kahden Alzheimer-potilaan haastattelusta. Haastattelu koostui tutustumistapaamisesta sekä varsinaisesta haastattelusta, joka toteutettiin musiikkia kuuntelemalla ja muistoista keskustelemalla. Aineiston analyysissä on käytetty eksistentiaalis-fenomenologian analyysimallia. Haastatteluista kävi ilmi, että haastateltavat…
Kodin merkitys muistisairautta sairastavalle miehelle : puolison näkökulma
2013
Koti on tärkeä kontrollin tunteen antaja. Koti on jotain, johon kuulutaan. Sillä on sekä symbolinen että konkreetti merkityksensä. Turvapaikan antajana koti suojaa ikääntynyttä henkilöä. Koti on se paikka, jossa ikääntynyt henkilö haluaa asua toimintakyvyn heikentymisestään huolimatta. Ympäristö mahdollistaa toimijuuden ja yksilö vastaa ympäristön asettamiin haasteisiin omien voimavarojensa mukaisesti. Yksilön toimintakykyä ei ole vain fyysinen toimintakyky, vaan myös psyykkisellä toimintakyvyllä kompensaatiokeinoineen on merkityksensä toimijuudessa. Koti on toimintakenttä, ympäristö, jossa ja josta käsin toimintoja suoritetaan. Muistisairaus heikentää voimakkaasti sekä elämänlaatua että se…